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Abstract. Bilateral chronic anterior uveitis is an extra-articular feature of 
Juvenile Idiopathic Arthritis (JIA).  Although figures vary, uveitis occurs in 
approximately 11-13% of patients with this disease, and is most commonly associated 
with the female gender, oligoarthritis and presence of antinuclear antibodies. The 
disease has an insidious onset and is often asymptomatic.  Managing patients with 
JIA-associated uveitis remains challenging as the disease may prove to be refractory 
to traditional treatment regimens.  Stepwise immunomodulatory therapy is indicated 
for the treatment of JIA-associated uveitis, with new biological drugs being utilized 
last in cases of refractory uveitis.  Small scale studies and practice have provided the 
evidence to undertake randomized control trials to evaluate the efficacy, safety and 
cost-effectiveness of anti-TNF-α therapies, such as Infliximab and Adalimumab. 
These have demonstrated promising results, with further data awaited from ongoing 
trials for Adalimumab (as SYCAMORE and ADJUVITE trials). Lower grade 
evidence is supporting the use of newer biologics such as Rituximab, Daclizumab, 
Tocilizumab and Abatacept, in those cases refractory to anti-TNF-α therapy. 
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I. Introduction 
 
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of arthritides presenting 
in childhood. To meet the criteria for diagnosis set out by the International League of 
Associations for Rheumatology (ILAR), the child (under 16 years of age) must have 
unexplained arthralgia for a duration of 6 or more weeks.1 It is the most common 
arthritis to present in the pediatric population.2 Whilst joint pain and immobility are 
the most pertinent features, the most common extra-articular feature of JIA is uveitis, 
particularly anterior uveitis.  In some patients, uveitis proves to be refractory to 
standard therapeutic measures, presenting a management challenge to 
ophthalmologists.  This paper seeks to stress the importance of prompt recognition 
and management of JIA-associated uveitis and explores current research on the 
efficacy of biological agents for its treatment.  Based on a systematic review of the 
literature and our clinical experience, a guide used at the Bristol Eye Hospital, UK is 
provided for the escalating treatment of these complex patients. 
 
II. Definition and Epidemiology of Juvenile Idiopathic Arthritis 
 
JIA is an autoimmune condition in which dysregulation of pro-inflammatory 
cytokines results in activation of T-cells in the synovial tissue.3; 4  Data on incidence 
and prevalence vary and is possibly unreliable due to the heterogeneous nature of the 
disease and different classification criteria available. Prevalence is estimated to be 
between 0.07 - 4.01 per 1000 and the incidence between 0.008 - 0.226 per 1000.2 
Studies mainly focus on Caucasian populations so little is known about the 
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epidemiology of other races.  From European studies, it appears that the most 
common subtype is oligoarthritis (50-70%), followed by rheumatoid factor-negative 
polyarthritis (30%).5 
 
III. Genetics of Juvenile Idiopathic Arthritis 
 
Involvement of genetic factors in the etiology JIA has been strongly suggested by 
twin concordance studies. At 25-40%, twin concordance is much higher than the 
population prevalence.6  Although reports of multicase families are rare, one Finnish 
study indicated that siblings of patients appear to be at greater risk of developing JIA. 
Further research demonstrated this risk to be 15-30 times greater than the general 
population.7; 8; 9 
Data indicates specific polymorphisms in Human Leukocyte Antigen (HLA), 
Macrophage Inhibitory Factor (MIF) and Protein Tyrosine Phosphatase (PTPN22) 
genes could increase susceptibility to JIA, but these will only explain a portion of the 
overall genetic background of JIA as it is a complex genetic trait. 
A strong risk association has been found between certain forms of JIA and HLA 
alleles. The association appears strongest in oligoarthritis, particularly with HLA 
Class II alleles.  The association with HLA-DR has been shown in polyarticular 
arthritis,10 whilst HLA-B27 is associated with enthesitis-related arthritis. 
Conversely, some HLA alleles (B27 and DR4) have a protective influence in early 
age, yet pose a risk later on.11.  Some HLA allele profiling studies show that the 
presence of the HLA allele DRB1*1104 significantly increases the risk of developing 
uveitis in oligoarticular JIA,12; 13 but other larger studies are not so conclusive.14 
Studies have used JIA sibling pairs to determine the developmental role of genetics 
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for uveitis, but little conclusive evidence has been found for a specific genetic 
element.15; 16; 17 
Research has also implicated the MIF and PTPN22 genes. 
MIF has a role in production of inflammatory cytokines such as IL-1, IL-6, and IL-8, 
and also promotes macrophage intracellular killing and phagocytosis.  A review of 
current evidence into genetic susceptibility for JIA by Phelan et al. implicated a 
functional role for MIF in the pathogenesis of JIA, particularly the -173*C allele in 
systemic disease.18 
PTPN22 is an intracellular tyrosine phosphatase in T-cells, which lowers the threshold 
for T-cell receptor signaling. A single-nucleotide polymorphism (1858C/T; 
rs2476601) has been associated with JIA, as has the 1858*T allele.18; 19 
A dense genotyping study including 2,816 patients with JIA and 13,056 controls 
confirmed the previously known association of the HLA region, and PTPN2, and also 
identified 14 other loci associated with JIA, including genes involved in the IL-2 
pathway.20 
 
IV. Classification 
 
Nomenclature for childhood arthritis has varied over the years.  Since the ILAR 
published their new criteria in 2001, Juvenile Idiopathic Arthritis is the most widely 
used and accepted term, making older terms such as Still’s disease, juvenile chronic 
arthritis and juvenile rheumatoid arthritis obsolete.  ILAR set out seven subtypes 
encompassed under the term JIA, which vary in terms of presentation, clinical signs, 
severity and family history,21 namely: systemic arthritis, oligoarthritis (‘persistent’ 
and ‘extended’), rheumatoid factor-positive or negative polyarthritis, enthesitis-related 
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arthritis, psoriatic arthritis and undifferentiated arthritis. The epidemiology of these is 
listed in Table 1.  
 
A. Systemic Arthritis  
Systemic arthritis is the most severe form of JIA, and frequently begins with a 
characteristic spiking fever.  This can be coupled with a rash, myalgia, 
lymphadenopathy and hepatosplenomegaly, but polyarthritis may not present for 
weeks to months after the initial presentation.  Uveitis is extremely rare in this 
subtype. 
 
B. Oligoarthritis/Pauciarthritis  
Oligoarthritis is the most common subtype, occurring more frequently in girls than 
boys.  In the ‘persistent’ form, up to 4 joints are affected.  If after 6 months, the 
number of affected joints increases to more than 4, this is termed the ‘extended’ form.   
 
C. Rheumatoid factor-positive polyarthritis 
Rheumatoid factor-positive polyarthritis affects 5 or more joints in a rheumatoid 
factor (RF)-positive child. It tends to affect older children and teenagers. 
 
D. Rheumatoid factor-negative polyarthritis  
Rheumatoid factor-negative polyarthritis affects 5 or more joints. It presents at all 
ages peaking in a biphasic pattern at 2-4 years and 9-11 years.  It is more common 
than rheumatoid factor-positive polyarthritis.   
 
E. Enthesitis-related arthritis  
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Any number of joints may be affected in enthesitis-related arthritis along with 
inflammation of tendons or muscular attachment to bone.  It is most common in boys, 
and in addition to the above criteria, two or more of the following must also be 
present: HLA-B27 antigen positive, HLA-B27 associated disease in first-degree 
relative, sacroiliac joint tenderness, acute anterior uveitis or inflammatory 
lumbosacral pain. 
 
F. Psoriatic Arthritis  
Psoriatic arthritis is RF-negative coupled with signs and symptoms of psoriasis such 
nail changes, dactylitis, psoriatic plaques or a family history.  It is usually an 
asymmetric oligoarthritis. 
 
G. Undifferentiated Arthritis 
Patients who do not fulfill the criteria for any subtype, or patients who fulfill the 
criteria for more than one subtype have Undifferentiated Arthritis.1; 22; 23; 24 
 
V. Epidemiology of Juvenile Idiopathic Arthritis associated Uveitis 
 
Uveitis, inflammation of the uveal tract, is strongly associated with JIA.  All 
anatomical types of uveitis are associated with JIA, but anterior uveitis is by far the 
most common (83%).  Less frequently occurring are intermediate uveitis (9%), 
posterior uveitis (1%) and pan-uveitis (7%).25  Both girls and boys can be affected, 
although evidence suggests girls under the age of 7 at diagnosis of JIA have a greater 
risk of developing uveitis, as do anti-nuclear antibody (ANA) positive children 26. A 
recent study found that an elevated erythrocyte sedimentation rate appeared to be a 
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predictive factor for development of uveitis, together with young age at onset and 
presence of ANA.27 The precise prevalence of uveitis amongst children with JIA is 
uncertain as figures vary in current literature.  Figures between 8% and 45% have 
been quoted.25; 28; 29; 30; 31 
The largest review by Heiligenhaus in 2007 quotes a JIA-associated uveitis 
prevalence of 12%.  The study was population based with a cohort of 3271.  Of the 
12% with uveitis, 83% were ANA positive, 25% had extended oligoarthritis and 16% 
had persistent oligoarthritis.  Furthermore, those with JIA and uveitis had an earlier 
onset of arthritis compared to those with arthritis alone; mean age 3.8 versus 7.0 
respectively.  Anterior uveitis was the most common in the group at 83%.25   
A prospective observational case series by Kotaniemi et al detected uveitis in 24% of 
the 426-strong cohort. A high proportion of these were ANA positive (66%), and 
similarly oligoarticular arthritis was the most affected group at 27%.  Children with 
JIA and uveitis had an earlier mean age of diagnosis of arthritis compared to children 
with arthritis alone (4.8 versus 7.3yrs).29 
A Greek retrospective review studied the prevalence of JIA-associated uveitis. Of the 
cohort of 56, 45% had anterior uveitis.  28% of these had further ocular 
complications: cataracts (n=6), band keratopathy (n=4), posterior synechiae (n=3), 
glaucoma (n=1), phthisis bulbi (n=1) and hyphema (n=1). The mean age of 
developing uveitis was 56 months.30 
Saurenmann et al also reported young age at diagnosis, female sex, and presence of 
antinuclear antibodies as strong risk factors for development of uveitis. Oligoarthritis 
was reported as the subtype with the highest rate of uveitis, and rheumatoid factor 
positive-polyarthritis as the subtype with the lowest rate; although the relative 
contribution of these risk factors was different for the different subtypes of JIA.32 
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VI. Etiology/pathogenesis of JIA-associated Uveitis 
 
The pathogenesis of the JIA is very complex as it is clearly a heterogeneous and 
multi-factorial disease, with a likely distinct pathogenesis for the different types of 
JIA. Current research establishes a very different pathogenesis for oligoarthritis in 
contrast to systemic arthritis.  Oligoarthritis is likely an autoimmune disease, caused 
by an abnormality of the adaptive immune system mediated by an antigen-driven 
lymphocyte-response, with a subsequent imbalance between autoreactive Th1/Th17 
and regulatory T (Treg) cells, which leads to the loss of immune tolerance to self-
antigens.  However, systemic arthritis is considered an autoinflammatory disease (in 
contrast to autoimmune) with abnormality in the innate immune system leading to 
aberrant activation of phagocytes (monocytes, macrophages and neutrophils) with the 
increase of pro-inflammatory cytokines and chemokines (IL-1, IL-6, IL-18 and pro-
inflammatory S100-proteins).33 
The pathogenesis of JIA-associated uveitis is also complex and multi-factorial.  
Tissue studies have been performed, but these are usually carried out after years of 
chronic disease and so do not necessarily help to elicit the etiology of early phase 
disease.31 Parikh et al carried out an immunohistochemical study of the iris and ciliary 
body of one eye with JIA-associated anterior uveitis.  This demonstrated non-
granulomatous inflammation consisting predominantly of B cells and plasma cells 
with focal collections of CD20+ cells.  T cells were also present, but in fewer 
numbers, potentially due to previous use of an anti-TNF-α agent.34  However, these 
non-specific changes do not particularly help to determine the pathogenesis.  
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Given that ANA-positive JIA patients clearly have an increased risk for uveitis,35 
ANA could have a role in the pathogenesis of uveitis.  The reason for the association 
is not known, and no common nuclear antigen has been discovered.36 
Other antibodies against retinal S-antigen and the DEK oncoprotein have also been 
implicated but evidence is conflicting.  Edleston et al found no evidence for abnormal 
levels of antibodies to human or bovine retinal S-antigen in children with JIA-
associated uveitis.37 However, Petty et al found that an antibody to S-antigen in serum 
was present significantly more frequently in children with JIA-associated uveitis than 
in children with JIA alone, other rheumatology disorders or healthy controls, and the 
cellular response in peripheral blood lymphocytes, measured by lymphocyte 
transformation, was also more frequent in those patients with JIA-associated uveitis.38  
Murray et al found serum antibodies to the DEK protein to be characteristic of 
oligoarticular JIA,39 however Dong et al found anti-DEK autoantibodies related to 
autoimmune conditions in general rather than specifically to JIA.40  Walscheid et al 
described how antiocular serum antibodies to ocular cryosections from swine eyes 
were detected more frequently in JIA-associated uveitis than in control groups, 
correlating with a complicated uveitis course but not with uveitis activity or anti-
inflammatory treatment.41  Similarly, it has been also reported higher levels of 
transthyretin are present in the aqueous of patients with JIA-associated uveitis and 
silent chronic anterior uveitis compared to those of the other uveitis types and control 
groups.42 
Recently, a study has shown an association between parvovirus B19 and JIA-
associated uveitis. In this study an intraocular antibody production against parvovirus 
B19 was found by Goldmann-Witmer coefficient in 7 of 13 patients with JIA-
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associated uveitis and only 3 of 45 patients with anterior uveitis of undetermined 
origin. However the viral DNA was not detected by PCR in any of the cases.43 
Despite HLA associations, to date no clear auto-antigens or indeed autoantibody has 
been identified to implicate autoimmunity. 
 
VII. Clinical Picture of Juvenile Idiopathic Arthritis-associated Uveitis 
 
JIA-associated uveitis most frequently presents as a chronic anterior uveitis.  Arthritis 
usually precedes the development of uveitis, but in approximately 10% of cases, 
uveitis presents before arthritis.44; 45  When this is the case, treatment for the uveitis 
can delay the presentation of joint involvement.  A recent study suggests JIA-
associated uveitis has a biphasic course, with a second peak of activity in the early 
teens.46  There is little solid evidence regarding activity of JIA-associated uveitis in 
adulthood as follow-up studies are often discontinued once the patient is over 16 years 
of age.  JIA-associated uveitis can result in ocular complications such as cataracts, 
secondary glaucoma, synechiae, and band keratopathy.25 
 
VIII. Screening 
 
Due to the asymptomatic nature of JIA-associated uveitis, screening by slit lamp for 
uveitis is vital in children suffering from JIA.47 In the United Kingdom, The British 
Society for Pediatric and Adolescent Rheumatology (BSPAR) and the Royal College 
of Ophthalmologists (RCOphth) have produced joint screening guidelines for uveitis 
in JIA (accessed at 
https://www.bspar.org.uk/DocStore/FileLibrary/PDFs/BSPAR%20Guidelines%20for
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%20Eye%20Screening%202006.pdf), a modification of which is presented in Table 2.  
Specific screening schedules are suggested for different subtypes, taking into account 
the subtypes most at risk of developing uveitis. 
 
IX. Management 
 
A. Initial Management 
 
1. Corticosteroids 
 
Topical corticosteroid drops, such as prednisolone and dexamethasone, are the first 
line of treatment for JIA-associated uveitis. Studies have proved these to be more 
effective than placebo, however over time there are significant side effects, in 
particular raised intraocular pressure (IOP) and cataract formation.48 Overall the 
cumulative topical corticosteroid dose correlates with significant visual impairment.49  
Elevated intraocular pressure secondary to steroid use is known as a steroid response, 
and persistent or recurrent episodes of elevated IOP may result in secondary 
glaucoma.  Armaly et al used 85 healthy subjects to sub-categorize this steroid 
response into three groups: high, moderate and non-responders.  One third of the 
study population had an increased IOP after daily topical corticosteroid use for 4 to 6 
weeks, five percent of which were considered ‘high responders’ with elevations of 
IOP greater than 15 mmHg and a total IOP greater than 31 mmHg. Patients with 
rheumatoid arthritis were found to have higher rates of steroid responsiveness.50 
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Thorne et al. found that the incidence of new-onset cataract was increased in patients 
with JIA-associated uveitis taking topical corticosteroids (0.04/eye-year; 95% 
confidence interval 0.02-0.09).49 
In complex disease, more aggressive therapy may be required; high dose systemic 
steroids including pulsed intravenous methylprednisolone may be useful (at a dose up 
to 30 mg/kg to max of 1 g). Prolonged use of systemic steroids should be avoided in 
children where possible due the associated side effects, including growth retardation. 
 
2. Methotrexate 
 
Other agents may be considered if an adequate response to topical steroids is not 
achieved in children with severe disease.  According to the German guidelines for 
anti-inflammatory treatment of JIA-associated uveitis, Methotrexate should be 
considered when the intraocular inflammation has not responded to 12 weeks of 
topical corticosteroid treatment (maximally 3 times daily), or in those cases of 
recurring uveitis under a systemic corticosteroid dosage of more than 0.15 mg/kg 
body weight, or if there is a new development of uveitis complications.51 
The antimetabolite Methotrexate is a common and effective choice for treating both  
joint inflammation and ocular inflammation.  Although evidence for the use of 
Methotrexate in joint inflammation is strong, evidence specific to JIA-associated 
uveitis from randomized control trials and prospective studies is lacking.  Ayuso et al. 
conducted a retrospective analysis of 22 patients, 18 of which (82%) showed 
improvement of their uveitis with a significant decrease in activity of inflammation 
after 3 months of Methotrexate treatment.52  Relapse rates were high (69%), although 
remission after withdrawal of Methotrexate was significantly longer in those treated 
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for greater than 3 years (P = 0.009).  Heilingenhaus et al. reported the outcome of  
treatment with Methotrexate in 35 patients with JIA-associated uveitis, achieving 
control of the inflammation without topical steroids in 21 patients and with topical 
steroids in 7 cases.53  Another study looking at new uveitis onset among patients with 
JIA, showed a lower incidence of uveitis onset in the group treated with Methotrexate 
versus the group not treated with Methotrexate.54 
The mean time to pharmacology induced remission after starting Methotrexate in JIA 
associated uveitis has been reported to be around 4.25 months, with a mean duration 
of the remission in those who achieved remission of 10.3 months.55 
The side effect profile of Methotrexate includes gastrointestinal upset, peptic ulcers, 
stomatitis, mouth ulcers, rashes and infections.56 Patients on Methotrexate require 
regular blood monitoring. Full blood count (FBC) and liver function (LFT) 
monitoring is required fortnightly until a stable dose is achieved. Subsequently, 
monitoring of FBC and LFTs should be monthly for six months, and six-weekly 
thereafter. Urea and electrolytes and creatinine are monitored six monthly.  
Methotrexate can be administered orally, intramuscularly or subcutaneously. Folic 
acid supplements must be taken alongside the use of Methotrexate.31 
The recommended standard dose for the treatment of JIA with Methotrexate is 10-15 
mg/m2/week based on a 1992 randomized double-blind placebo-controlled trial in 
patients with resistant arthritis.57  Recent studies showed that the high-dose of 
Methotrexate is associated with greater risk of associated side effects, but no 
significant improvement in active joint count, so according to these results doses 
greater than 0.5 mg/Kg/week should be avoided.58 
 
3. Mycophenolate mofetil 
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Mycophenolate mofetil (CellCept) is used to prevent rejection in transplants and stops 
the proliferation of lymphocytes.  It has also been shown to be a useful adjunct in 
those with refractory uveitis with no joint involvement, resulting in improvement in 
uveitis and sparing the use of corticosteroids.59 Some reports in adults, including 
patients with JIA-associated uveitis, have demonstrated Mycophenolate mofetil may 
be effective in maintaining vision and improving visual acuity.60   
In the pediatric population, Mycophenolate mofetil has also shown efficacy on the 
treatment of pediatric uveitis.  In a study by Doycheva et al. including 17 children 
with uveitis (4 with JIA-associated uveitis), Mycophenolate mofetil achieved a 
steroid-sparing effect in 88% of the patients, with complete discontinuation of oral 
prednisolone in 41%.  24% of the patients remained relapse-free during the treatment, 
and a reduction in the relapse rate was observed in all other patients except one.59 In 
another study by Chang et al including 52 patients with pediatric uveitis (25 with JIA-
associated uveitis), 73.1% achieved inflammation control after 2 months of treatment 
with Mycophenolate mofetil monotherapy. However, the treatment had to be stopped 
due to side effects in 6 patients (11.5%), specially gastrointestinal disturbances.61 
No randomized controlled trials have been performed in this area. It should be noted 
that Mycophenolate mofetil is not routinely used in patients with severe joint disease 
because it is not considered to be effective in treating arthritis.  A randomized 
controlled trial found no difference between placebo and Mycophenolate mofetil in 
terms of disease improvement in patients with refractory rheumatoid arthritis.62 
The recommended dose for the use of Mycophenolate mofetil in JIA-associated 
uveitis is 1000-1500 mg/m2 divided in two doses.59 
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4. Cyclosporin 
 
A multicentre retrospective study of 82 patients looked into the effects of oral 
cyclosporin on the treatment of active uveitis in patients with JIA already taking 
topical or systemic steroids or other immunomodulatory agents. Inactive uveitis 
during the treatment period was only achieved in around 25% of the patients and 
cyclosporin failed to control  macular edema in all  patients included with this 
complication. When cyclosporin was used in combination with another 
immunomodulatory agent, the percentage of patients with inactive uveitis during the 
follow-up increased to around 50%.63 
The use of cyclosporin as a monotherapeutic second line agent in the treatment of 
JIA-associated uveitis is not advised, but it could be used in combination with another 
second line agent. 
The recommended dose of cyclosporin for the treatment of JIA-associated uveitis is 
<3mg/Kg/day separated in 2 equal doses.51 
 
5. Leflunomide 
 
Recently, a retrospective study looked into the efficacy of leflunomide versus 
methotrexate in the treatment of JIA-associated uveitis. A total of 15 patients were 
included, and a higher rate of uveitis flare-up was associated with the use of 
leflunomide.64 
 
B. Biological Agents 
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Increasingly, children with uveitis refractory to topical corticosteroids, methotrexate 
and mycophenolate mofetil, or those who are intolerant of standard 
immunosuppressive agents are commenced on biological therapy.  Biological agents 
are used to target and block the action of inflammatory cytokines or their receptors in 
order to prevent the autoimmune response.  The biological agents most commonly 
used target TNFα, a pro-inflammatory cytokine which activates T cells.  Other newer 
targets are CD20+ cells, interleukin receptors IL-2 and IL-6, and the B7 receptor on 
antigen presenting cells. 
 
1. Infliximab 
 
Infliximab is a chimeric (murine-human) monoclonal antibody administered by 
intravenous infusion which is repeated at 2 weeks and then every 4-8 weeks. 
Infliximab targets TNF-α,65 the exact effect in biologic-induced apoptosis, 
cytotoxicity, and modulation of inflammatory cell trafficking remain unclear, however 
TNF antagonists in general act through two main mechanisms: those mechanisms 
mediated by TNF receptor (TNFR) blockage and those mediated by inhibitor binding 
to transmembrane TNF (tmTNF).66 Given the results of several small observational 
studies, evidence suggests Infliximab may have a positive effect on reducing ocular 
inflammation. 
Elevated concentrations of TNF-α in the serum and synovial fluid of JIA patients has 
been previously reported and reinforces the rationale of using anti-TNF-α for the 
treatment of JIA.67 However the levels of TNF-α in serum do not correlate with the 
activity or severity of the disease.68 
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A retrospective analysis by Kahn et al. studied the use of high dose Infliximab (10-20 
mg/kg/dose) on 17 children with refractory uveitis, 10 of whom had JIA.  All 17 
patients had a positive response. In 13 patients, there was no evidence of intraocular 
inflammation after 2 intravenous infusions.  The remaining 4 required up to 7 
infusions to achieve quiescence and visual acuity improvement.  No side effects were 
reported.69 However bearing in mind the short mean follow-up (13 months) in this 
study and the good outcomes in other studies using smaller doses of Infliximab, the 
higher dose of Infliximab treatment is not recommended by the authors. 
Tynjala et al. evaluated the use of Infliximab and Etanercept in the treatment of 
chronic uveitis associated with JIA.   Forty-five patients were enrolled. Of those 
taking Infliximab (3–6 mg/kg), 42% experienced improvement (decrease in number of 
anterior chamber cells), whereas 20% of those taking Etanercept improved.70 
A small retrospective study by Sharma et al. undertaken in a clinical setting looked at 
6 patients who took Infliximab (maximum dose 6 mg/kg) concomitantly with 
Methotrexate and corticosteroids. They noted 3 patients with JIA-associated uveitis 
entered drug induced remission and 2 had improvement of ocular inflammation. The 
corticosteroid dosage was able to be gradually reduced whilst receiving Infliximab, 
indicating a ‘steroid-sparing role’ for Infliximab. Infliximab was tolerated well in this 
study with no reported side effects.71  
A study by Richards et al. supports the steroid-sparing role of Infliximab. 6 patients 
with JIA-associated uveitis were weaned off corticosteroids whilst on Infliximab.  
This study used a high dose of Infliximab, and all 6 patients experienced reduced 
ocular inflammation with no side-effects.72 
In another study by Ardoin et al, 16 patients were treated with Methotrexate and 
median maintenance Infliximab (dose of 8.2 mg/kg) at a mean of 5.6 weeks intervals. 
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64% had complete control of ocular inflammation at 1 year, and 79% had no 
inflammation or a two-step decline in inflammation. Topical steroids were 
discontinued in 69%, and 58% remained free of uveitis recurrence at 1 year without 
any reported adverse event.73 
One study looking into the safety of Infliximab in the treatment of JIA included 348 
patients, where 214 were on treatment with Infliximab. The most commonly observed 
adverse events included mild infections, infusion or injection site reactions and 
alanine aminotransferase elevations. In this study no cases of malignancies or 
tuberculosis reactivation were reported. New-onset uveitis occurred in 9 patients, 
psoriasis or psoriasiform lesions in 13 and inflammatory bowel disease in 6.74 
Infliximab is a chimeric antibody and the production of human anti-chimeric 
antibodies against Infliximab has been implicated in some anaphylactic reactions as 
well as the loss of effectivity over time.75 
These small studies give a strong indication of the potential therapeutic role of 
Infliximab.  However, as of yet no randomized controlled trials have been completed, 
so stronger evidence to support this is not available.  Due to the lack of RCTs, the use 
of Infliximab is not approved for the treatment of JIA-associated uveitis and it is an 
off-label indication. 
 
2. Adalimumab 
 
Adalimumab (Humira) is a human monoclonal antibody against TNF-α.  It has the 
advantage of being self-administered as a subcutaneous injection. 
Zannin et al. looked retrospectively at the 91 patients with JIA-associated uveitis 
refractory to steroids, methotrexate and cyclosporin A listed in the National Italian 
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Registry.  48 received Infliximab and 43 received Adalimumab. Forty-seven patients 
(55.3%) achieved control of ocular inflammation, 28 (32.9%) had recurrent uveitis, 
and 10 (11.8%) maintained a chronic course. The remission rate was higher with 
Adalimumab (67.4% versus 42.8% with Infliximab; p = 0.025).  No serious adverse 
events occurred, but 8 (8.8%) experienced 11 minor adverse events (9 with 
Infliximab, 2 with Adalimumab).  These were infection (upper respiratory tract, 
herpes zoster and urinary tract infection), infusion reactions, and systemic symptoms 
such as headache, irritability and an urticarial rash.  The latter adverse events were 
linked with the use of Infliximab in all cases. Ocular complications (cataracts, vitritis, 
cystoid macular edema and ocular hypertension) decreased from 0.47 to 0.32 per 
subject.76 
Tynjala et al. performed a retrospective observational study of 20 patients with JIA-
associated uveitis. 95% had tried previous anti-TNF-α therapy (Infliximab or 
Etanercept), were given 40mg Adalimumab every 2 weeks for a mean duration of 18 
months.  35% showed improvement, 60% showed no change and 5% showed 
worsening of activity of uveitis.  No serious side effects were seen in this study. The 
35% who showed improvement were younger and had a shorter disease duration.77.   
Another retrospective analysis of 18 patients with JIA-associated uveitis administered 
20-40mg Adalimumab every 2 weeks. Treatment of uveitis was defined by change in 
relapse rate: ‘effective’ treatment was classified as no relapse or >2 fewer relapses 
than before treatment.  Treatment for uveitis was ‘effective’ in 88%. Arthritis (graded 
using the American College Rheumatology pediatric criteria) showed improvement in 
81%.  No adverse reactions were reported.78 
The efficacy of Adalimumab has been evaluated in a recent study of 94 patients, 54 of 
whom had JIA-associated uveitis.  The outcome measure was change in uveitis 
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activity measured using the Standardized Uveitis Nomenclature (SUN) criteria.79 
Uveitis significantly improved in 28% of patients (2-fold decrease in uveitis activity), 
and in this group corticosteroid drop usage was stopped in 31% and decreased to 1-2 
drops/day in 35%. 16 (30%) experienced a moderate response, 16 (30%) had no 
response and 7 (13%) experienced worsening uveitis (a two-fold increase in uveitis 
activity).  Improvement in arthritis was reported in those with JIA-associated uveitis: 
after 24 months, 27% had active joint disease, compared to 67% at the start.  The dose 
of Adalimumab varied in this study as patients with a high degree of uveitis activity 
received weekly doses. The authors concluded Adalimumab clearly has a positive 
effect, and it potentially should be given in combination with Methotrexate.80  
Another small study by Tynjala et al. (n=21) showed similar results, with 53% 
showing improvement of ocular inflammation after Adalimumab.  19% showed no 
change, and uveitis activity increased in 26% of patients.81 
Another study compared the efficacy of Adalimumab vs Infliximab in the treatment of 
chronic non-infectious childhood uveitis, which included 16 patients, 12 being 
diagnosed with JIA-associated uveitis. This study concluded that in the long term (3 
years) Adalimumab had a higher uveitis remission than Infliximab.82 
Current evidence would suggest that Adalimumab is beneficial in treating uveitis but 
so far studies have been small and do not provide strong evidence.  Two large Phase 
III, randomized, double-blind, placebo-controlled, multicenter trials (The Sycamore 
Trial and the ADJUVITE trial) are currently underway. The Sycamore Trial is 
comparing the clinical effectiveness of Adalimumab in combination with 
Methotrexate versus placebo in combination with Methotrexate in patients with active 
JIA-associated uveitis refractory to only Methotrexate therapy.  The results of this, 
expected in 2018, should shed light on the efficacy, safety and cost-effectiveness of 
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Adalimumab. (Accessed at http://www.sycamoretrial.org.uk/).  The Independent Data 
Safety & Monitoring Committee (IDSMC) have recently reviewed the interim data 
and concluded there is enough data from 90 patients to support the use of 
Adalimumab in the treatment of JIA and Uveitis. The ADJUVITE trial 
(NCT01385826) is a study comparing the efficacy of Adalimumab versus placebo on 
reducing intraocular inflammation assessed by laser flare photometry after 2 months 
of treatment in patients with active uveitis in spite of combined treatment with topical 
steroids and Methrotexate. 
Adalimumab has been reported as a relatively safe drug with few side effects. In 
general terms however, JIA-uveitis studies are limited by the size sample and duration 
of follow-up.  Therefore the long-term safety of these treatments have been mostly 
assessed in rheumatology studies rather than uveitis studies. A large randomized 
controlled trial (n=284) using Adalimumab to treat Rheumatoid Arthritis found only 2 
adverse events which occurred with 10% or greater frequency with Adalimumab than 
with placebo. The first was reactions occurring at the injection site such as erythema 
and/or itching, hemorrhage, swelling, or pain.  These were reported in 21 (29%), 16 
(23%), and 21 (29%) patients receiving Adalimumab 20, 40, and 80 mg respectively, 
versus 4 (6%) patients randomized to placebo (p < 0.01 v placebo for all 
comparisons).  The second adverse event was hyperlipidemia (triglycerides >2.26 
mmol/l ).  This was reported in 18 (25%), 22 (31%), and 22 (31%) patients receiving 
adalimumab 20, 40, and 80 mg respectively, versus 13 (19%) patients receiving 
placebo.  Serious infections occurred in 4 (2%) patients taking Adalimumab. These 
were gastroenteritis, mild bronchitis, urinary tract infection and bacterial infection of 
unknown source with fever.83 Smaller studies in the specific case of JIA have been 
also published regarding the safety of Adalimumab. A study in a German population 
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regarding the safety of Adalimumab in JIA found a rate of 50.9 per 100 patient-years 
of adverse events.  Of which, only 11 were reported as serious (2.5 per 100 patient-
years).84 Another multicentric study in polyarticular JIA included 32 patients treated 
with adalimumab from 2 to 4 years of age. Severe adverse events were reported in 5 
patients (16 %).85 
Adalimumab is approved by the European Medicines Agency (EMA) for the use in 
active polyarticular JIA from 2 years of age and active enthesitis-related arthritis from 
6 years of age. 
 
3. Etanercept 
 
The anti-TNF-α biologic Etanercept is a fusion protein produced through expression 
of recombinant DNA.  Etanercept has been used successfully to manage JIA.86  
However, evidence from a number of small studies and a randomized control trial 
suggests it is less effective than other biologics at treating JIA-associated uveitis.  
In 2005, Smith et al. conducted a small placebo controlled, double-blinded RCT 
looking at a cohort of 12 patients with JIA-associated uveitis. 7 patients received 
Etanercept twice a week (0.4mg/kg) and 5 took a placebo.  They concluded there was 
no difference between Etanercept and the placebo, with 3 out of 7 in the Etanercept 
group and 2 out of 5 in the placebo experiencing reduced ocular inflammation 
(p=1.0).  No serious adverse events occurred.87  
A study suggested that rather than reducing ocular inflammation, Etanercept may 
precipitate endogenous uveitis.  Six patients (3 of which had JIA), received 25mg of 
Etanercept twice a week for joint inflammation.  A positive result was seen with 
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regard joint inflammation, but all 6 patients developed uveitis for the first time which 
resolved after changing to Infliximab.88 
Another study looked into the results of 229 questionnaires completed by JIA patients 
taking Etanercept.  Thirty-one patients (13.5%) had a history of uveitis before 
commencing Etanercept, and uveitis recurred in 19 of these patients whilst taking 
Etanercept. 2 other patients experienced uveitis for the first time.86 The authors 
concluded the frequency and severity of uveitis seemed unaffected by Etanercept.  
Despite this evidence being rather weak, this remains in line with the results of the 
randomized control trial.  Therefore, despite Etanercept being an effective drug to 
treat joint inflammation in JIA,89 it does not have the evidence base for the treatment 
of JIA-associated uveitis. 
Recently, a study including 3467 patients with JIA, showed that the rate of developing 
uveitis while on combination of Etanercept and methotrexate is similar than the rate in 
patients on methrotexate alone, for what seems unlikely that Etanercept may 
precipitate uveitis.90 
Etanercept has been approved by the EMA for JIA in patients aged 2 to 17 years who 
have polyarthritis and extended oligoarthritis, adolescents aged 12 to 17 years who 
have psoriatic arthritis or adolescents aged 12 to 17 years who have enthesitis-related 
arthritis and have not responded adequately to or cannot take Methotrexate. 
 
4. Golimumab 
 
Golimumab has also been used to treat JIA-associated uveitis. Golimumab is a human 
monoclonal antibody targeting TNF-α licensed for use in rheumatoid arthritis, 
psoriatic arthritis and ankylosing spondylitis.   
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A 2011 case report states 40mg Golimumab every 4 weeks was effective in treating a 
case of JIA-associated uveitis refractory to all previous anti-TNF therapy.  On taking 
Golimumab concomitantly with Methotrexate for 7 months, the patient entered 
remission.91 
A set of 3 case studies from 2012 indicate that Golimumab can be used in cases of 
JIA-associated uveitis refractory to Infliximab, Etanercept and Adalimumab to 
achieve quiescence of inflammation to such an extent that surgery is possible.  
However in 1 case, arthritis and uveitis activity worsened despite Golimumab.92  
The results of a phase III study to assess efficacy and safety of subcutaneous 
Golimumab in polyarticular JIA patients with active arthritis refractory to 
methotrexate have been preliminary reported. It showed a rapid response of active 
arthritis to the treatment with Golimumab. However it failed to meet the primary 
endpoint, as there was no significant difference in arthritis flare between the 
Golimumab and placebo group, after 12 weeks of open-label Golimumab.A 
Further evidence regarding the use of Golimumab is required. 
The use of Golimumab in JIA is off-label. 
 
5. Rituximab  
 
The CD20+ marker on B-cells has been indicated in the autoimmune process of JIA-
associated arthritis.  Rituximab, a chimeric monoclonal antibody targeting the CD20 
marker, may be a useful treatment for JIA-associated uveitis. 
Heiligenhaus et al. carried out a retrospective case series from 2011 used Rituximab 
in 10 patients who had uveitis refractory to corticosteroids, disease modifying anti-
rheumatic drugs (DMARDs) and at least one anti-TNF.  After one treatment course, 7 
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out of 10 patients had inactive uveitis and improved arthritis, although uveitis 
reoccurred in 3 of these within 6-9 months.93 
 A smaller study (n=8) concluded that following the use of Rituximab, refractory JIA-
associated uveitis remained in remission in 7 out of 8 patients, with 5 patients being 
able to discontinue immunosuppressants and 2 discontinuing topical corticosteroids.  
No adverse events were reported.94  These small studies suggest Rituximab could be 
beneficial for both refractory uveitis and arthritis. 
The use of Rituximab in JIA is off-label. 
 
 
6. Daclizumab 
 
Daclizumab is a human monoclonal antibody to the IL-2 receptor of T-cells.  It has 
been shown to be effective in treating adult uveitis, but there is little evidence 
regarding children.95 An interventional prospective case series in 2009 trialed 
Daclizumab in JIA-associated uveitis.  It looked prospectively at 6 children taking 
high dose Daclizumab for refractory uveitis. Four out of six had reduced active 
inflammation at week 12, however, 3 patients were withdrawn from the trial before 
the end of the study due to failure to control the intraocular inflammation, 
uncontrolled joint disease or side effects such as rash.96 At present Daclizumab is no 
longer manufactured due to diminishing market demand and available alternative 
treatments. 
 
7. Tocilizumab 
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Approved for treatment of arthritis, Tocilizumab is an anti-IL-6 receptor antibody.  
The only documented use of Tocilizumab for JIA-associated uveitis is a small study 
administering 8mg/kg every 4 weeks to 3 patients with refractory uveitis.  2 of the 3 
responded and inactivity of uveitis was achieved, and in all 3 arthritis improved.  No 
adverse events or side effects occurred.97 
An open-label trial to assess the efficacy and safety of Tocilizumab in the 
management of JIA-associated uveitis refractory to other immunomodulatory 
treatments is currently recruiting patients in the USA (NCT01603355). 
The use of Tocilizumab has been approved in children from 2 years of age with active 
systemic arthritis and polyarthritis. 
 
8. Abatacept 
 
Unlike other biologics, Abatacept is a soluble fusion protein that results in T cell 
inactivation by binding to CD80/CD86 on antigen presenting cells. It consists of the 
extracellular domain of human cytotoxic T lymphocyte antigen 4 (CTLA4) and the 
modified FC domain of human IgG1. Several case studies have indicated the role of 
Abatacept for treating JIA-associated uveitis, although no RCT has yet been 
performed. 
A 2008 case report concluded that Abatacept (10mg/kg IV) induced remission of 
uveitis over a period of 12 months, with no adverse reactions or infections, and doses 
of concomitant medications were tapered off.98   
Elhai et al. report two further cases. Both patients had JIA-associated uveitis 
refractory to at least 2 anti-TNFs. Treatment with Abatacept (10mg/kg IV), induced 
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remission. The two patients remained in remission for both uveitis and arthritis after 
10 and 16 months.  No drug reactions occurred.99 
A final case report demonstrated that Abatacept induced remission of uveitis, yet not 
arthritis, in a 20 year old with refractory JIA-associated uveitis.100 These results are 
mirrored in a small study in which 7 patients with JIA-associated uveitis refractory to 
at least 2 anti-TNFs were treated with 10mg/kg Abatacept monthly.  Six out of seven 
achieved remission with no side effects after 9 months of treatment, but 1 patient 
withdrew due to arthritis flare and oral mycosis.101 
A recent retrospective study included 21 patients with active JIA-associated uveitis 
treated with Abatacept after being refractory to at least 1 anti-TNF-α  treatment. 
Uveitis control was achieved in 11 patients, but there was recurrence in 8 patients at 
the early follow-up and in the remaining 3 at later follow-up. Three patients 
developed new ocular complications while on Abatacept.102 
Further studies with a higher number of patients are warranted to establish the real 
role of Abatacept in JIA-associated uveitis as the current reported evidences of 
efficacy are anecdotic. 
Abatacept is approved in moderate to severe active polyarthritis in adolescents and 
children from 6 years of age who have not had a sufficient response to other 
medicines including one TNF blocker. 
 
X. Bristol Eye Hospital Protocol 
 
Patients who have complex uveitis and concomitant joint disease should be managed 
in a multidisciplinary clinic with senior ophthalmologists, rheumatologists and 
specialist nurses from a pediatric and ophthalmology background. 
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At present there is no approved treatment protocol for treating patients with JIA-
associated uveitis in the United Kingdom. The following is a guide used at The Bristol 
Eye Hospital for the escalating treatment of these complex patients.  It is based on 
current literature and clinical experience, although results of randomized controlled 
trials currently being undertaken will influence future treatment regimens. 
 
Corticosteroid Drops 
Children presenting with mild uveitis associated with JIA are started on the topical 
corticosteroid [PredForte (prednisolone acetate 1%)] 4-6 x a day, which is then 
tapered. Cyclopenolate 0.5-1% is used at night to reduce the risk of posterior 
synechiae formation. In our experience it is unlikely that children and their families 
will manage drops administered more than 4 drops a day for prolonged periods.  
 If after 3 months, control of intraocular inflammation has not been achieved (0-0.5+ 
cells in the anterior chamber according to SUN scale79) or more than 2 drops of 
steroid are required to control the uveitis (as the treatment with ≤3 drops daily of 
topical corticosteroid have been associated with an 87% lower risk of cataract 
formation compared with eyes treated with >3 drops daily49), or repeated prolonged 
courses of topical corticosteroids are required, escalation of treatment to systemic 
immunotherapy should be considered.  
 
Methotrexate  
Methotrexate is  the immunosuppressant of choice in JIA-associated uveitis in view of 
its extensive use in managing children with JIA as described above. Methotrexate is 
used for children with uveitis who have failed treatment with topical steroids or who 
have active uveitis with ocular complications, such as a cataract.  It is administered by 
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mouth or subcutaneously 10–15 mg/m2 once weekly to a maximum of 20 mg oral or 
25 mg by subcutaneous injection once weekly.    It may take up to 3 months of 
treatment to take effect and although severe side effects are uncommon, they include 
bone marrow suppression as well as hepatotoxicity.  Folic acid 5mg per week 
(administered on a different day to the Methotrexate) reduces the adverse reactions 
encountered. 
If after 6 months of treatment with Methotrexate, control of intraocular inflammation 
has not been achieved, the switching of Methotrexate to Mycophenolate mofetil in 
those patients intolerant to Methotrexate could be considered.  Little et al. 
demonstrated that the addition of a second immunomodulatory agent such as 
Mycophenolate mofetil did not showed substantial benefits but may lead to an 
increase in adverse effects,103. If there is a failure of the conventional 
immunomodulatory treatment after 3 months of treatment, escalating to biologic 
agents such as Adalimumab (Humira) is indicated. 
 
Adalimumab  
In the Bristol Eye Hospital, Adalimumab is currently accessed via the Sycamore trial 
or via NHS exceptional funding following suboptimal response to Methotrexate 
and/or Mycophenolate mofetil. We would advocate early escalation to a biologic such 
as Adalimumab in cases of uncontrolled disease despite the above treatment. 
Adalimumab is administered by subcutaneous injection.  A dose of 24 mg/m2 (max. 
40 mg) on alternate weeks is used in children aged 4-12 years old and 40 mg on 
alternate weeks is used in children aged 13-17 years old, with review if there is no 
treatment response within 12 weeks. 
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In exceptional cases where the combination of Adalimumab and Methotrexate fails to 
control the ocular inflammation, Infliximab is considered, with the second infusion at 
2 weeks and then 6 and 8 weekly. In the cases of poor response shorter intervals 
including 4 and 6 weeks periods could be considered. 
In cases were Infliximab is not adequate also to control the intraocular inflammation 
other therapies such as Tocilizumab or Abatacept are considered. 
 
 
XI. Assessing Response 
 
The multinational interdisciplinary working group for uveitis in childhood proposed a 
standardized outcome measurement for clinical trials in JIA-associated uveitis. 
Consensus was reached that clinical outcomes should be reported at defined time 
points in longitudinal studies and patients should be stratified by prognostic markers. 
Visual acuity testing should be age appropriate. The severity of uveitis should be 
measured as anterior chamber cell grade according to the criteria of the SUN working 
group,79 and duration of active inflammation should be recorded. Visually significant 
structural complications should be documented and quantified with standard measures 
and treatment response, as well as corticosteroid-sparing achievement, should be 
detailed. Age-specific quality of life questionnaires are recommended.104 
The use of ‘Laser flare photometry’ has been proposed as it may provide a more 
accurate way of assessing response to treatment. This is an objective quantitative 
method that enables accurate measurement of aqueous flare and cells with high 
reproducibility. Laser flare photometry allows detection of subclinical alterations in 
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the blood–ocular barriers, identifying subtle pathological changes that could not have 
been recorded otherwise.105  
 
XII. Treating Complications 
 
Long-standing inflammation can lead to sight threatening complications, which must 
be treated alongside the uveitis. 
The presence of ocular complications (such as band keratopathy, posterior synechia, 
cataract, ocular hypertension/glaucoma, hypotony, epiretinal membrane, optic nerve 
edema, macular edema or vitreous opacity) at presentation is estimated between 45-
67% with JIA associated uveitis.25; 106 The Systemic Immunosupressive Therapy for 
Eye Disease Study (SITE), in a cohort of 327 patients with JIA-associated uveitis, 
showed that 60% of the eyes had at least 1 ocular complication at the presentation. 
The incidence of developing new complications was estimated to be 0.15/eye-year, 
and this rate was lower (0.04/eye-year) in those cases that did not have complications 
at presentation.107 There is a higher risk of developing complications among those 
patients with severe disease at onset,45 posterior synechiae, active anterior chamber 
inflammation >1 + cells, and previous intraocular surgery.107 Male gender has also 
been associated with the development of complications and poor outcomes.108; 109 
The most frequent complication is cataract, although some reports established a 
higher frequency for band keratopathy and posterior synechiae.28; 106 Significant risk 
factors for the development of cataract included posterior synechia, active intraocular 
inflammation, and topical corticosteroid use at presentation.49 
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Band keratopathy can be eliminated by chelating agents or laser surgery, but Najjar et 
al. found that after EDTA chelation, recurrence was common (60%) in cases of 
uveitis.110; 111 
For cataracts, standard phacoemulsification and intraocular lens (IOL) implants are 
indicated. Although the IOL implantation has been controversial, there is increasing 
evidence that this is a safe procedure with current surgical techniques.112 However 
Magli et al. reported a higher incidence of secondary glaucoma in patients undergoing 
primary IOL implantation compared to  secondary implantation.113  In our unit, we 
use an aggressive pre- and post-operative course of topical and systemic 
corticosteroids, such as IV methylprednisolone and systemic prednisolone.  Ideally 
both eyes should be free of inflammation for 3 months prior to surgery.114; 115; 116  
Increased ocular pressure secondary to the inflammation and/or steroid use is treated 
with topical antihypertensives. If the response is poor and raised IOP and secondary 
glaucoma persists, trabeculectomy or drainage tube surgery may be considered.115; 117; 
118  A recent study investigating the use of goniotomy in the treatment of childhood 
uveitis glaucoma, which included 20 patients with JIA, reported promising results in 
the use of this technique with 15 of 35 patients requiring no further surgery.68 
Macular edema may be treated with systemic corticosteroids, local corticosteroids and 
potentially an anti-VEGF agent such as bevacizumab (Avastin).  Mackensen et al. 
found intravitreal bevacizumab to be an effective and safe treatment although the 
effect may be transient, and re-injections may be necessary.119; 120 
 
XII. Method of Literature Search 
A search of the MEDLINE database was performed by using the PubMed website for 
the years 1966 through 2013, inclusive. The search terms employed were uveitis, 
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iritis, iridocyclitis, epidemiology, juvenile idiopathic arthritis, juvenile chronic 
arthritis, juvenile rheumatoid arthritis, and juvenile arthritis. All articles considered to 
be of clinical significance taken into account. Main emphasis was laid on articles from 
recent years. The bibliography of each publication was reviewed for articles not 
captured by the MEDLINE search. Those articles which included additional 
information and were considered to be of clinical importance were included. 
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